Back to discover
Disease
Migraine with Aura
Late-stage therapeutic developmentEmerging research
2
Publications
24
Clinical trials
1
Related conditions
2023
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Migraine and cardiovascular disease: what cardiologists should know.
Research2023-08-01European heart journal
Advances in genetics of migraine.
Research2019-06-21The journal of headache and pain
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 6 clinical trials expected to report results, the earliest in Q1 2028.
Upcoming Milestones
- Q1 2028A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age.
- Q1 2029A Comparative Effectiveness Study of Oral Medications Used for Migraine Prevention: The APT Comparison Study
- Q1 2029Phase 3, Multicenter, Randomized, Double-blind, Group Sequential, Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age
- Q3 2030Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age
- Q1 2031A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age
Major developments
Major trial resultsHigh impact
Results posted2026-07-02
Major trial resultsHigh impact
Results posted2026-06-16
Clinical MilestonesView all 14Hide
Results posted
- 2026-07-02A Randomized, Double-Blind, Parallel-Group, Active Controlled Trial With Open-Label Safety Extension to Evaluate the Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Subjects Requiring Preventive Treatment of Migraine (TEMPLE)Results posted
- 2026-06-16A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic MigraineResults posted
Results expected
- 2026-07-14A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age.Results expected Q1 2028
- 2026-07-09A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 Years of AgeResults expected Q4 2031
- 2026-07-09Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of AgeResults expected Q3 2030
- 2026-07-09Phase 3, Multicenter, Randomized, Double-blind, Group Sequential, Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of AgeResults expected Q1 2029
- 2026-06-29A Comparative Effectiveness Study of Oral Medications Used for Migraine Prevention: The APT Comparison StudyResults expected Q1 2029
Recently completed
- 2026-04-30Safety and Efficacy of Zonisamide Versus Topiramate in MigraineCompleted
- 2026-01-07A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM])Completed
- 2025-12-22A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of AgeCompleted
- 2025-10-20A Phase 3, Multicenter, Open-Label 156-Week Extension Study To Evaluate The Long-Term Safety And Tolerability Of Oral Atogepant For The Prevention Of Migraine In Participants With Chronic Or Episodic MigraineCompleted
Other updates
- 2026-02-04A Prospective, Open-Label Study Examining the Use of Rimegepant ODT 75 mg or Zavegepant Nasal Spray 10 mg for Acute Treatment of Migraine in the Emergency Department SettingTerminated
- 2025-12-04A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2Terminated
+6 more in the activity timeline below
Activity timeline14
- 2026-07-14ClinicalA Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age.Results expected Q1 2028
- 2026-07-09ClinicalA Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 Years of AgeResults expected Q4 2031
- 2026-07-09ClinicalPhase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of AgeResults expected Q3 2030
- 2026-07-09ClinicalPhase 3, Multicenter, Randomized, Double-blind, Group Sequential, Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of AgeResults expected Q1 2029
- 2026-07-02ClinicalA Randomized, Double-Blind, Parallel-Group, Active Controlled Trial With Open-Label Safety Extension to Evaluate the Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Subjects Requiring Preventive Treatment of Migraine (TEMPLE)Results posted
- 2026-06-29ClinicalA Comparative Effectiveness Study of Oral Medications Used for Migraine Prevention: The APT Comparison StudyResults expected Q1 2029
- 2026-06-16ClinicalA Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic MigraineResults posted
- 2026-06-04ClinicalA Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of AgeResults expected Q1 2031
- 2026-04-30ClinicalSafety and Efficacy of Zonisamide Versus Topiramate in MigraineCompleted
- 2026-02-04ClinicalA Prospective, Open-Label Study Examining the Use of Rimegepant ODT 75 mg or Zavegepant Nasal Spray 10 mg for Acute Treatment of Migraine in the Emergency Department SettingTerminated
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approved & established therapies
Lasmiditan Succinateapproved
Approval — RAYVOW is indicated for the acute treatment of the headache phase of migraine attacks, wi… (2022)
Rimegepantapproved
Approval — Vydura is indicated for the Acute treatment of migraine with or without aura in adults;… (2022)
Clinical trials
The current development programme across all trial phases.
Clinical programme
24
6
18
6
Late-stage studies
Recruiting
Recently completed
Evidence coverage
How much of this condition's readable clinical evidence the confidence engine has incorporated, across its most-studied treatments. This measures coverage of the evidence base — not whether any treatment works.
High evidence coverage
Largest gap: no meaningful change (2, trial-readability).
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
First approvals
2022emaApproval — Lasmiditan Succinate· RAYVOW is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults. source ↗
2022emaApproval — Rimegepant· Vydura is indicated for the Acute treatment of migraine with or without aura in adults; Preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month. source ↗
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
20192023
Most influential
Major themes7
- Brain Ischemia1
- Cardiologists1
- Cardiovascular Diseases1
- Foramen Ovale, Patent1
- Migraine Disorders1
- Migraine with Aura1
- Stroke1
Leading journals2
- European heart journal1
- The journal of headache and pain1
Leading researchers8
- Albury CL1
- Appelman Y1
- Couturier EGM1
- Dahdal J1
- de Winter RJ1
- El Bouziani A1
- Griffiths LR1
- Kalkman DN1
Affiliations (unnormalised)5
- Department of Clinical and Experimental Cardiology1
- Erasmus MC University Medical Center1
- Genomics Research Centre1
- Heart Center1
- Icahn School of Medicine at Mount Sinai1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
A subtype of migraine disorder, characterized by recurrent attacks of reversible neurological symptoms (aura) that precede or accompany the headache. Aura may include a combination of sensory disturbances, such as blurred VISION; HALLUCINATIONS; VERTIGO; NUMBNESS; and difficulty in concentrating and speaking. Aura is usually followed by features of the COMMON MIGRAINE, such as PHOTOPHOBIA; PHONOPHOBIA; and NAUSEA. (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.